The European Commission (EC) has granted marketing authorisation for Lilly’s Kisunla (donanemab) in early symptomatic Alzheimer's disease (AD). It is approved in adults with mild cognitive impairment as well as those with mild dementia stages of AD with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers. "Kisunla demonstrated meaningful results in people […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!